Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 13Cholangiocarcinoma 2Pancreatic Neoplasms 1Locally Advanced Thyroid Gland Carcinoma 1Liver Neoplasms 1Hepatocellular Carcinoma with PVTT 1Digestive System Neoplasms 1Differentiated Thyroid Cancer 1Diabetes Mellitus 1Cirrhosis, Familial, with Pulmonary Hypertension 1Carcinoma 1Biliary Tract Adenocarcinoma 1Biliary Malignant Tumors 1

Interventions

donafenib 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Biliary Malignant Tumors × donafenib × Clear all
NCT06685289 2025-01-28

Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence Risk

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Recruiting
70 enrolled
Gastrointestinal

Biliary Malignant Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡